Center-Authored Papers

Filters: Author is Durie, Brian G M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Z
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B.  2010.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).. Blood. 116(26):5838-41. Abstract
S
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL et al..  2015.  Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma.. Blood. Abstract
K
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger WI, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R et al..  2009.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.. Blood. 114(9):1729-35. Abstract
J
Jagannath S, Durie BGM, Wolf JL, Camacho ES, Irwin D, Lutzky J, McKinley M, Potts P, Gabayan AE, Mazumder A et al..  2009.  Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.. British journal of haematology. 146(6):619-26. Abstract
H
Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak AJ, Crowley J, Barlogie B.  2009.  Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3510-7. Abstract
C
Cavo M, Rajkumar VS, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M et al..  2011.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.. Blood. 117(23):6063-73. Abstract
B
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH et al..  2010.  Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.. British journal of haematology. 148(4):562-8. Abstract
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract